Karolinska Development’s portfolio company Dilafor recruits first patient to Phase 2a study of tafoxiparin in women diagnosed with preeclampsia
27 October 2021 - 5:00PM
Karolinska Development’s portfolio company Dilafor recruits first
patient to Phase 2a study of tafoxiparin in women diagnosed with
preeclampsia
STOCKHOLM, SWEDEN – October 27, 2021. Karolinska Development AB
(Nasdaq Stockholm: KDEV) announces today that the portfolio company
Dilafor, a drug development company focusing on the development of
tafoxiparin for obstetric indications, has enrolled the first
patient in a clinical Phase 2a study with tafoxiparin in pregnant
women diagnosed with preeclampsia.
Dilafor has now enrolled the first patient in a Phase 2a pilot
study that will investigate whether treatment with subcutaneously
administered tafoxiparin can improve the outcome of preeclampsia.
To explore the treatment efficacy and clinical benefit, ultrasound
examinations of the mother and fetus as well as measurment of a
panel of established biomarkers for preeclampsia will be
performed.
The exploratory, open label, randomized, parallel-group, Phase
2a pilot study will evaluate the safety, tolerability and efficacy
of daily subcutaneous tafoxiparin treatment from the time of
diagnosis for up to 4 weeks. The study is planned to include 23
pregnant women in 26 to 34 weeks of gestation who are diagnosed
with preeclampsia. The pregnant women will be randomized to either
subcutaneous injection of tafoxiparin and standard of care or only
standard of care, which is usually symptomatic treatment with
anti-hypertensive drugs.
“The unmet medical need in preeclampsia is enormous, and due to
the complexity of the condition it remains a signficant hurdle in
women’s health and obstretics. We welcome Dilafor’s initiative to
investigate the potential of tafoxiparin in this challenging
medical condition and are looking forward to take part of the Phase
2a study results", comments Viktor Drvota, CEO of Karolinska
Development.
Preeclampsia is diagnosed in 5–8% of all pregnant women globally
and can lead to severe fetal and maternal complications. One third
of cases are severe in degree with extreme risk of preterm birth
and maternal and fetal sequela. Long-term vascular complications,
including stroke and cardiovascular problems, are reported early in
life in women with a history of preeclampsia. The condition
consistently remains among the top three causes of maternal death
in both high-income and low-income countries.
Karolinska Development's direct ownership in Dilafor amounts to
1% and indirect ownership interest via KDev Investment in Dilafor
amounts to 30%.
For further information, please
contact:
Viktor Drvota, CEO, Karolinska Development AB Phone: +46 73 982
52 02, e-mail: viktor.drvota@karolinskadevelopment.com
Johan Dighed, General Counsel and Deputy CEO, Karolinska
Development ABPhone: +46 70 207 48 26, e-mail:
johan.dighed@karolinskadevelopment.com
TO THE EDITORS
About Karolinska Development ABKarolinska
Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences
investment company. The company focuses on identifying breakthrough
medical innovations in the Nordic region that are developed by
entrepreneurs and leadership teams. The Company invests in the
creation and growth of companies that advance these assets into
commercial products that are designed to make a difference to
patients' lives while providing an attractive return on investment
to shareholders.
Karolinska Development has access to world-class medical
innovations at the Karolinska Institutet and other leading
universities and research institutes in the Nordic region. The
Company aims to build companies around scientists who are leaders
in their fields, supported by experienced management teams and
advisers, and co-funded by specialist international investors, to
provide the greatest chance of success.
Karolinska Development has a portfolio of ten companies
targeting opportunities in innovative treatment for
life-threatening or serious debilitating diseases.
The Company is led by an entrepreneurial team of investment
professionals with a proven track record as company builders and
with access to a strong global network.
For more information, please visit
www.karolinskadevelopment.com.
- KD Dilafor start phase 2a ENG 27 Oct
Karolinska Development Ab (LSE:0P3C)
Historical Stock Chart
From Mar 2024 to Apr 2024
Karolinska Development Ab (LSE:0P3C)
Historical Stock Chart
From Apr 2023 to Apr 2024